drugset / Trial / NCT00051948

TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer

NCT00051948

Phase 1/2 Completed 28 enrolled Telik
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a dose-ranging, open label, Phase 1-2a study of TLK286 in combination with Paraplatin (carboplatin) in patients with recurrent ovarian cancer.

Timeline

Start
2003-01
Primary completion
2005-01
Completion
2005-01

Drugs

EvaluationDrugModalityDoseRoute
Subject canfosfamide Small molecule

Indications